Credit: Liberate Bio

Melissa Deck profile page

Director of Platform

at Liberate Bio

Melissa Deck is a strategic scientific leader with deep expertise in molecular biology and nonclinical development across the pharma, biotech and startup sectors. She has led high-impact programs involving CRISPR/Cas9 genome editing, LNP screening and AAV gene therapy. With a background in in vivo pharmacology, assay development and editing platforms, Melissa has directed cross-functional teams and external collaborations to advance novel therapeutics. Currently director of platform at Liberate Bio, she previously held leadership roles at Carver Biosciences, Arbor Biotherapeutics and Gemini Therapeutics, consistently driving innovation in nucleic acid-based drug development and delivery.

Got a Question for Melissa Deck?

Get in touch using the contact form linked here and we'll get back to you shortly.

Content Written By, Reviewed By, or Featuring Melissa Deck

Total: 1

3D illustration of an RNA strand representing genetic material used in gene delivery.

Industry Insight

Overcoming the Gene Therapy Delivery Challenge

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances in lipid nanoparticles and protein barcoding are enabling more precise, scalable, tissue-specific delivery.